Finlay Institute is a Cuban pharmaceutical institution devoted to research, development, production and commercialization of vaccines, at the service of human medicine.

The competence of its one thousand qualified workers, innovation, product development, updated technology, modern facilities designed and operated under high GMP standards support Finlay Institute. We have established an efficient Quality Assurance System recognized in several national and international regulatory inspections included the WHO.

We produce and commercialize conventional vaccines included in the Extended Immunization Program and others applied in outbreaks and epidemics. We also commercialize several active pharmaceutical ingredients (API) for vaccines.

Portfolio of vaccines
- VA-MENGOC-BC® BC meningococcal vaccine
- vax-MEN-AC® AC meningococcal vaccine
- vax-SPIRAL® Trivalent leptospirosis vaccine
- vax-TyVi® Vi polysaccharide Salmonella typhi vaccine
- vax-TET® Tetanus vaccine
- VA-DIFTET® diphtheria/tetanus vaccine, pediatric formulation
- dT diphtheria/tetanus vaccine for adults
- DTP Diphtheria / Tetanus / Pertussis vaccine

Portfolio of API
- Neisseria meningitidis outer membrane vesicles
- Bordetella pertussis inactivated cells
- Vi Polysaccharide active raw ingredient
- Sterile purified tetanus toxoid
- Sterile purified diphtheria toxoid

Main R & D projects
- Plain and conjugated meningococcal vaccines (polysaccharide A, C, Y and W135)
- Conjugated pneumococcal vaccines
- Attenuated and inactivated cholera vaccines (oral)
- Tuberculosis vaccines
- Adjuvants